HYD

HYD LLC is a research-driven biotechnology company based in Hungary that specializes in the development and application of deuterium depletion technology for therapeutic purposes. Established in 1993, the company is a pioneer in studying the biological significance of naturally occurring deuterium and its role in cellular signaling and growth regulation. Their core business involves the production of deuterium-depleted water (DDW) and the development of pharmaceutical-grade DDW products for cancer treatment and metabolic disorders. HYD's research demonstrates that lowering deuterium levels in the body can inhibit tumor growth and improve metabolic health by influencing sub-molecular regulatory mechanisms. The company currently markets consumer health products and veterinary drugs while advancing clinical trials for human pharmaceutical applications.